Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider

Oslo, Norway, 9 January 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 9 January 2026, regarding a share issue of 6,826,200 shares (the "Offer Shares") pursuant to a board authorisation granted by the Company's extraordinary general meeting on 29 April 2025. As of this date, the Company has been informed that Saturn Invest AS, a close associate to primary insider Brynjar Forbergskog, subscribed for 2,222,222 Offer Shares. Saturn Invest AS was allocated 2,222,222 Offer Shares at a price of NOK 9.00 per Please see the attached form for further details about the transaction. Disclosure regulation: This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Gjest Breistein, CFO gjest.breistein@lytixbiopharma.com +47 952 60 512 About Lytix Biopharma: Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.